Circulating CCR6+ILC proportions are lower in multiple sclerosis patients
Florentina Aglas-Leitner1,2, Pierre Juillard1, Anette Juillard1
1Vascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health The University of Sydney Sydney NSW Australia.
Insights
Innate lymphoid cells (ILC) play a role in multiple sclerosis (MS). CD56bright natural killer (NK) cells expand during relapse, and altered helper ILC proportions suggest changes in central nervous system (CNS) migration in MS patients.
Area of Science:
- Immunology
- Neuroimmunology
- Cellular Biology
Background:
- The role of innate lymphoid cells (ILC), especially helper ILC, in the pathogenesis of multiple sclerosis (MS) remains unclear.
- Understanding ILC dynamics in MS is crucial for developing targeted therapies.
Purpose of the Study:
- To comprehensively analyze peripheral ILC subsets in MS patients before and after alemtuzumab treatment.
- To investigate MS-related immunophenotypic shifts in ILC using mass cytometry and advanced computational analysis.
Main Methods:
- Mass cytometry was employed to analyze circulating ILC subsets in MS patients and non-MS controls.
- Alemtuzumab treatment effects were assessed by comparing ILC profiles pre- and post-administration.
- Fast interpolation-based t-SNE (Flt-SNE) was used for dimensionality reduction to elucidate ILC immunophenotypic shifts.
Main Results:
- Alemtuzumab treatment did not alter overall levels of natural killer (NK) cells or helper ILC (ILC1, ILC2, ILC3).
- CD56bright NK cell expansions were observed in relapsing MS patients.
- MS patients showed proportional shifts from ILC1 to ILC2 and decreased proportions of CCR6+ helper ILC prior to alemtuzumab treatment.
Conclusions:
- CD56bright NK cell expansion during relapse suggests an immediate immune response to disease reactivation in MS.
- CCR6-related shifts in helper ILC indicate potential alterations in their migration to the central nervous system (CNS) in MS patients.
Objectives:
The role of innate lymphoid cells (ILC), particularly helper ILC, in the pathogenesis of multiple sclerosis (MS) is not well understood. Here, we present a comprehensive analysis of peripheral ILC subsets in MS patients prior and after alemtuzumab administration using mass cytometry.
Methods:
Circulating ILC were analysed by mass cytometry in MS patients before and after alemtuzumab. These were compared with non-MS controls. MS-related shifts among ILC immunophenotypes were further elucidated by fast interpolation-based t-SNE (Flt-SNE) dimensionality reduction.
Results:
Neither natural killer (NK) cells nor helper ILC (ILC1, ILC2 and ILC3) levels were altered following alemtuzumab treatment. However, CD56bright NK cell expansions were observed in relapsing patients. MS patients prior to alemtuzumab further displayed proportional shifts from ILC1 to ILC2, with MS-associated decreases in CCR6+ helper ILC proportions.
Conclusion:
CD56bright NK cells during relapse indicate an immediate response to disease reactivation, while CCR6-related shifts among helper ILC suggest altered ILC migration to the CNS during MS.
More Related Videos
07:39Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
